Seven law firms whose stars had dimmed in the eyes of general counsel are once again shining bright, and two up-and-coming legal sparklers are suddenly radiating excellence, according to a new survey of corporations’ favorite firms.
Skadden Arps Slate Meagher & Flom LLP stands alone among elite law firms in the arena of client service thanks to a concerted long-term effort to respond to client feedback, according to a new survey of corporate counsel.
The fickle feelings of corporate counsel are apparent once again in an annual survey gauging which law firms deliver the most sterling client service, as one-third of last year's favorites were cast aside after being outflanked by hungry rivals.
There are more arrogant law firms than in years past, according to a new survey of corporate counsel, but one familiar firm has risen above them all.
The number of law firms that Fortune 1000 clients say offer excellent client service grew by 9.8 percent over the past year, a sign that firms with broader services are separating themselves from the competition, according to a new survey of corporate counsel.
Attentive client service, not size, continues to be the critical factor for general counsel at the world's largest corporations, according to a recent survey of corporate counsel, who gave top marks to a mix of large and midsize law firms.
Litigation matters are expected to spike in the coming year, but budget-conscious general counsel expect firms to do whatever it takes to make sure they stick to the bottom line — and that includes settling and settling early, a new survey of in-house counsel said.
With litigation on the rise, law firms are looking for a bigger piece of the pie these days, but they won't get it unless they start to think more creatively about how to attract and retain clients, a new survey of in-house counsel said.
Four firms strike fear in the hearts of corporate counsel more than any others thanks to their relentless approach to high-stakes litigation and a knack for building legal teams that go for the jugular, according to a new survey.
The U.S. Judicial Panel on Multidistrict Litigation has rejected a higher percentage of centralization requests in recent years, a trend the head of the panel told Law360 was due in part to a rise in patent cases and other types of litigation he said were more likely to center on individual issues.
An application for a new testosterone replacement drug by Endo Pharmaceuticals has serious safety risks that may outweigh its benefits, according to a report by U.S. Food and Drug Administration reviewers released Tuesday ahead of an advisory committee meeting on the new drug application.
Rising use of social media and digital advertising among drugmakers and medical device firms hasn’t led to stepped-up enforcement by the U.S. Food and Drug Administration for improper promotional activities, despite uncertainty about how the agency will police such activities, according to a recent report.
Medicare has recovered just a sliver of as much as $70 million in overpayments to suppliers of durable medical equipment despite a mandate that such companies obtain bonds to guarantee taxpayers can recoup excessive reimbursement, according to a report issued Wednesday.
A significantly smaller percentage of in-house counsel used some form of alternative legal fee structures last year, according to a new legal survey from Fulbright & Jaworski LLP that defied previous years' upward trends and more vocal criticism in recent years of the billable hour.
The percentage of in-house counsel expecting an increase in whistleblower suits hit a three-year high in 2012, as companies braced for more tipsters to come forward under a potent new Dodd-Frank Act program, according to a survey released Tuesday by Fulbright & Jaworski LLP.
Corporations beefed up their legal departments in 2012 and expect to do the same this year, according to a new report, with mounting regulatory challenges and abundant litigation combining to boost the need for in-house expertise.
In-house corporate lawyers last year rated fixed-fee legal pricing the most effective alternative fee model to the straight billable hour, according to an annual Fulbright & Jaworski LLP survey released Tuesday.
Corporate counsel singled out nearly 100 litigators as the most client service-driven in their field thanks to their innate ability to deliver solid outcomes, effectively communicate litigation strategy and prioritize their clients' business interests.
An administrative judge for Philadelphia's trial court system reported Thursday that efforts to reduce a significant backlog of pharmaceutical and asbestos mass tort cases were succeeding, and ordered that reformed procedures for these cases continue.
The Federal Trade Commission has taken enforcement action on nearly every pharmaceutical merger it has examined in depth since 1996, according to data the antitrust watchdog released Friday.
Plaintiffs have proven remarkably agile in adopting new theories as to when “natural” claims are false or misleading, and it may be tempting for advertisers to try to predict the next angle of attack and adjust their ads accordingly. But a recent class action reminds us that the basic principles of advertising law — substantiation and consumer understanding — are the best defenses, say Barry Benjamin and John Knapp of Kilpatrick Townsend & Stockton LLP.
For the time being, patience and compliance are the only options for U.S. medicine and medical device manufacturers who require licenses to export their products to Iran. Waiting for an export license may be difficult, but the consequence of not having one can be a bitter pill to swallow, say attorneys at Reed Smith LLP.
No document review mechanism guarantees perfection, but the adoption of predictive coding has the potential to drastically alter the way in which documents are reviewed and produced in complex pharmaceutical and medical device litigation, says Jessica Sykora of Norton Rose Fulbright.
You might have heard this before — a cancer patient was treated with Aredia/Zometa, which, it is claimed, caused the patient to suffer from osteonecrosis of the jaw. A lawsuit is filed, the patient subsequently dies from the cancer, the plaintiff lawyers do not file the requisite paperwork to substitute in a new party, and the case is dismissed. But the defendant is not prejudiced by this kerfuffle, right? Wrong, says Stephen McConnell of Reed Smith LLP.
In light of the proposed e-discovery amendments to the Federal Rules of Civil Procedure, businesses need to set themselves up to efficiently respond to discovery and requests for information from their counsel by implementing and following document-control policies as part of normal business practices. The failure to do so will eventually consume vast amounts of employee time, say Steven Cvitanovic and Colin Murphy of Haight Brown & Bonesteel LLP.
While the technology at issue in Commil USA LLC v. Cisco Systems Inc. was not life sciences, the implications of the Federal Circuit's decision, and the trend in the law it reflects, likely will be significant for companies that often rely on method-of-treatment, mechanism-of-action and method-of-manufacturing patents as key value drivers. Such patents may be materially weakened, say Eric Marandett and Diana Huang of Choate Hall & Stewart LLP.
In Rowland v. Novartis Pharmaceuticals Corp., three Pennsylvania plaintiffs — merely because they were rousted to multidistrict litigation — received the advantage of the different choice-of-law rules for states to which they had no connection, rather than being bound by the choice-of-law rules of their actual domiciliary state. Where, as in Rowland, the plaintiff is a pure litigation tourist, this is an absurd result, says James Beck of Reed Smith LLP.
There are several unique defenses, depending on the state, available to defendant pharmaceutical companies which arise from the discord between consumer protection statutes and prescription drugs, say Yvonne McKenzie and Gabriel Vidoni at Pepper Hamilton LLP.
In addition to continued headline-grabbing litigation involving pharmaceutical companies in the wake of PLIVA Inc. v. Mensing, 2013 brought a number of important cases informing everything from class certification questions and product labeling trends to False Claims Act liability and fracking disputes, say attorneys at Weil Gotshal & Manges LLP.
China's Food and Drug Administration recently announced changes to its Drug Registration Rules, which, while demonstrating the agency’s determination to foster innovation, may not achieve a balance between multinational drug companies and domestic competitors in its current shape, says Katherine Wang of Ropes & Gray LLP.